EP1750701A1 - Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique - Google Patents

Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique

Info

Publication number
EP1750701A1
EP1750701A1 EP05756511A EP05756511A EP1750701A1 EP 1750701 A1 EP1750701 A1 EP 1750701A1 EP 05756511 A EP05756511 A EP 05756511A EP 05756511 A EP05756511 A EP 05756511A EP 1750701 A1 EP1750701 A1 EP 1750701A1
Authority
EP
European Patent Office
Prior art keywords
clopidogrel
clopidogrel hydrochloride
solution
hydrochloride
amorphous form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05756511A
Other languages
German (de)
English (en)
Inventor
Vladimir Kaznakov
Eva Veverkova
Miroslav Veverka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ivax Pharmaceuticals sro
Original Assignee
Ivax Pharmaceuticals sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412172A external-priority patent/GB0412172D0/en
Priority claimed from GB0418395A external-priority patent/GB0418395D0/en
Application filed by Ivax Pharmaceuticals sro filed Critical Ivax Pharmaceuticals sro
Publication of EP1750701A1 publication Critical patent/EP1750701A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a novel, amorphous form of clopidogrel hydrochloride, to processes for the preparation thereof, to a pharmaceutical composition comprising the novel amorphous form, and to use of the amorphous form as a blood platelet aggregation inhibitor and an antithrombotic agent.
  • Clopidogrel (administered as its hydrogensulfate salt) is a well known inhibitor of induced platelet aggregation. It acts by inhibiting the binding of adenosine phosphate to its receptor.
  • the chemical name of clopidogrel is methyl (+)-(S)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine- 5(4H)-acetate. It may be represented by the formula (I) below:-
  • Clopidogrel was described in the patent EP 0099802 and in Example 1 was purified without any details by means of its hydrochloride, m.p. 130-140 °C. The patent is completely silent about the crystal form of the product and IR or XRPD data.
  • Example 12 methyl (2-chloro ⁇ henyl)-6,7-dihydrothieno[3,2- c]pyridene-5(4H)-acetate hydrochloride hydrate is prepared by dissolving methyl (2-chlorophenyl)-6,7- dihydrothieno[3,2-c] ⁇ yridene-5(4H)-acetate in acetone, and adding a solution of cone, hydrochloric acid at 5-10 °C. The product slowly crystallizes, m.p. 138-140 °C. The product was identified by elementary analysis, IR, spectrum, ⁇ -NMR investigation.
  • Example 21 the methyl (+)-(S)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridene-5(4H)- acetate hydrochloride is prepared by dissolving of dextrarotatory methyl (2-chlorophenyl)-6,7- dihydrothieno[3,2-c]pyridene ⁇ 5(4H)-acetate intermediate in diethyl ether and introducing anhydrous gaseous hydrogen chloride into the solution.
  • (+)-(S)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridene-5(4H)-acetate hydrochloride is prepared in a similar way.
  • the process for the preparation of form II comprises dissolving of (+)-(S)-(2- chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridene-5(4H)-acetate in solvent(s) and admixing with a solution of hydrogen chloride.
  • the process according to the claims comprises using acetone, acetonitrile, ethyl acetate. In the example, mixture is stirred 16 hrs at room temperature. Crystalline product, form II is filtered off and characterized by melting point 143-144 °C.
  • amorphous versus crystalline is their solubility.
  • the bioavailability is one of the key parameters determining the form of the substance to be used in pharmaceutical formulation.
  • the present invention provides clopidogrel hydrochloride in amorphous form.
  • the present invention also provides a process for preparing clopidogrel hydrochloride in amorphous form, comprising the step of preparing a solution of clopidogrel hydrochloride in a polar, a dipolar or a less polar aprotic solvent, or a mixture thereof, admixing the solution with an antisolvent to precipitate clopidogrel hydrochloride and separating the clopidogrel hydrochloride.
  • the present invention provides a process for the preparation of clopidogrel hydrochloride in amorphous form, comprising the step of preparing a solution of clopidogrel hydrochloride in a polar, a dipolar or a less polar aprotic solvent, or a mixture thereof, removing the solvent from the solution to obtain a residue, admixing the residue with an antisolvent to precipitate clopidogrel hydrochloride and separating the clopidogrel hydrochloride.
  • the present invention provides a process for the preparation of clopidogrel hydrochloride in amorphous form, comprising the step of preparing a solution of clopidogrel hydrochloride in a polar, a dipolar or a less polar aprotic solvent, admixing the solution with an antisolvent, removing the polar, dipolar or less polar aprotic solvent from the solution to precipitate clopidogrel hydrochloride and separating the clopidogrel hydrochloride.
  • the present invention provides a process for the preparation of clopidogrel hydrochloride in amorphous form, comprising the step of preparing a solution of clopidogrel hydrochloride in acetone, a Ci-Q alcohol, such as methanol or ethanol, or tetrahydrofuran, and removing the solvent from the solution.
  • a Ci-Q alcohol such as methanol or ethanol, or tetrahydrofuran
  • the present invention provides a process for the preparation of the amorphous form of clopidogrel hydrochloride in a protic, a polar, a dipolar or a less polar aprotic solvent selected from Ci to Os alcohols, tetrahydrofuran, acetonitrile, to C ⁇ ketones, dimethylf ormamide, water and mixture thereof.
  • Preferred anti-solvents are C2 to Q ethers, Ci to Q acetates, cyclohexane, toluene.
  • the present invention provides a process for the preparation of clopidogrel hydrochloride in amorphous form, which comprises adding hydrogen chloride to a solution of clopidogrel in a solvent selected from a Q-Cs dialkyl ether, a Cs-Cs linear, branched or cyclic hydrocarbon and mixtures thereof, to precipitate clopidogrel hydrochloride; and separating the precipitated clopidogrel hydrochloride from the solvent.
  • a solvent selected from a Q-Cs dialkyl ether, a Cs-Cs linear, branched or cyclic hydrocarbon and mixtures thereof
  • FIG. 1 is a powder X-ray diffraction (XRPD) pattern of the amorphous form of clopidogrel hydrochloride.
  • Sample surface plain, in nickel sample holder, measured and stored at room temperature.
  • FIG. 2 is is a FTIR spectrum of the amorphous form of clopidogrel hydrochloride.
  • FIG. 3 is is a differential scanning calorimetric (DSC) thermogram of the amorphous form of clopidogrel hydrochloride.
  • Equipment Differential scanning calorimeter Perkin-Elmer DSC-7. The temperature scale was calibrated using the standards In, Sn and Zn. The enthalpic scale was calibrated to the enthalpy of In fusion. Samples of 3-4 mg were placed in standard aluminum pans, nitrogen was used as a purge gas. In the records, endothermic peaks are oriented upwards. The records were corrected for the baseline. DSC profile is characterized by broad endothermic peak about 65-80 °C and sharp endothermic peak about 125 °C, due to the decomposition.
  • the present invention provides a novel amorphous form of clopidogrel hydrochloride.
  • the new form is characterized by powder X-ray diffraction pattern (Fig.l).
  • the pattern is without intense focused reflections and is featureless except for a halo with a maximum about 12.3, 24.1 degrees two-theta.
  • the amorphous form is highly pure. More preferably, it is essentially free of crystalline clopidogrel hydrochloride. Most preferably the amorphous clopidogrel hydrochloride is free of crystalline clopidogrel hydrochloride, within the detection limit of a powder X-ray diffractometer comparable to the instrumentation described. The purity of clopidogrel hydrochloride can be assessed by a comparison of the XRPD pattern of an unknown sample with those of mixtures of authentic pure amorphous and pure crystalline clopidogrel hydrochloride.
  • the amorphous form produces a differential scanning calorimetric (DSC) thermogram
  • the present invention further provides a process for the preparing a novel amorphous form of clopidogrel hydrochloride comprising the steps of preparing a solution of clopidogrel hydrochloride in a polar, dipolar or a less polar aprotic solvent, removing the solvent from the solution to obtain a residue, admixing the residue with an antisolvent to precipitate clopidogrel hydrochloride, and separating the clopidogrel hydrochloride.
  • the solution of clopidogrel hydrochloride in a polar, dipolar or less polar aprotic solvent may be heated to increased the solubility of the clopidogrel hydrochloride.
  • the polar, dipolar or less polar aprotic solvent may be selected from Ci to Q alcohols, tetrahydrofuran, acetonitrile, C3 to C ⁇ ketones, dimethylformamide, water and mixtures thereof. After dissolution, the solution may be cooled, preferably to room temperature.
  • the aforementioned polar, dipolar or less polar aprotic solvent may optionally be removed from the solution to obtain a foam or oily residue.
  • the removal of the solvent is carried out in the processes of the present invention by evaporation.
  • the solvent/solvents are removed be evaporation under ambient or reduced pressure. The antisolvent in such a case is then added to the foam or the oily residue.
  • a solution of clopidogrel hydrochloride in a polar, dipolar or less polar aprotic solvent may be slowly added to the antisolvent in order to precipitate clopidogrel hydrochloride.
  • antisolvents are C2 to Q dialkyl ethers, Ci to C4 acetates, toluene.
  • the ether is diethyl or methyl t.-butyl ether or toluene.
  • a precipitate forms in the antisolvent.
  • the precipitate should be separated from reaction mixture at early stage, preferably within a few hours.
  • the precipitate may be collected by techniques well-known in the art e.g. filtration, centrifugation.
  • the precipitate may be dried under ambient or reduced pressure
  • the present invention also provides a process for the preparation of clopidogrel hydrochloride comprising the steps of preparing a solution of clopidogrel hydrochloride in a polar, dipolar or less polar aprotic solvent, admixing the solution with an antisolvent, removing the polar, dipolar or less polar aprotic solvent from the solution to precipitate clopidogrel hydrochloride and separating the clopidogrel hydrochloride.
  • the antisolvent is toluene or cyclohexane.
  • the antisolvent is heated to a temperature of about room temperature to reflux so that the clopidogrel hydrochloride becomes more soluble in the antisolvent, with temperatures at or near reflux being preferred.
  • the resulting mixture is preferably cooled to about room temperature, though one skilled in the art may appreciate than other temperatures may be achieve the same result.
  • the polar, dipolar or less polar aprotic solvent and antisolvent are removed, preferably by evaporation, to leave amorphous form.
  • the present invention provides a process for preparation the amorphous form of clopidogrel hydrochloride comprising the steps of preparing a solution of clopidogrel hydrochloride in a solvent selected from Ci to Q alcohols, tetrahydrofuran, acetonitrile, C3 to Ce ketones, dimethylformamide, water and mixtures thereof and removing solvent to obtain the amorphous form.
  • a solvent selected from Ci to Q alcohols, tetrahydrofuran, acetonitrile, C3 to Ce ketones, dimethylformamide, water and mixtures thereof.
  • the mixture of clopidogrel hydrochloride and solvent is heated to form a solution.
  • a mixture is heated to reflux for a few hours.
  • the solution is preferably cooled to about room temperature. ⁇ ie solution may be stirred for a few hours.
  • the solvent is removed to obtain a powder, which is the amorphous form of clopidogrel hydrochloride.
  • the solvent may be evaporated and temperature may be increased.
  • the conditions and yield may vary when starting with clopidogrel base rather than clopidogrel hydrochloride prepared in reaction mixture.
  • the present invention also provides a process for the preparation of clopidogrel hydrochloride in amorphous form, which comprises adding hydrogen chloride to a solution of clopidogrel in a solvent selected from a Q-Q dialkyl ether, a Cs-Cs linear, branched or cyclic hydrocarbon and mixtures thereof, to precipitate clopidogrel hydrochloride; and separating the precipitated clopidogrel hydrochloride from the solvent.
  • the Cs-Cs linear, branched or cyclic hydrocarbon may be, for example, a Cs-Cs linear, branched or cyclic alkane.
  • the dialkyl ether may be selected, for example, from diethyl ether, diisopropyl ether, and tert-butyl methyl ether and the Cs-Cs linear, branched or cyclic hydrocarbon may be selected, for example, from n-hexane and cyclohexane.
  • the hydrogen chloride is conveniently added to the solution of clopidogrel at a temperature in the range of from -15 to 25 B C.
  • the mixture of the solvent and precipitate of clopidogrel hydrochloride is conveniently maintained at a temperature of from -15 to 25 a C for from 20 to 120 minutes prior to separating the clopidogrel hydrochloride from the solvent.
  • the hydrogen chloride may be added to the solution as a gas or as a solution of hydrogen chloride in a solvent selected from a Q-Cs dialkyl ether, a Cs-Cs linear, branched or cyclic hydrocarbon and mixtures thereof. In one embodiment, from 0.9 to 1.5 molar equivalents of hydrogen chloride are added to the solution of clopidogrel.
  • the separated clopidogrel hydrochloride may conveniently be dried in a vacuum at a temperature below 30 S C.
  • compositions of the present invention contain clopidogrel hydrochloride amorphous form, optionally in mixture with other form(s) and active ingredients. Excipients are added to the composition for variety of purposes. Diluents (e.g. macrocrystalline cellulose, talc, calcium carbonate, magnesium oxide) increased the bulk of solid pharmaceutical composition, and may make a pharmaceutical dosage form containing the composition easier for patient and care give to handle. Binders for solid pharmaceutical compositions include, e.g., dextrin, gelatin, povidone, maltodextrin. Disintegrants include, e.g., colloidal silicon dioxide, crospovidone, starch.
  • Diluents e.g. macrocrystalline cellulose, talc, calcium carbonate, magnesium oxide
  • Binders for solid pharmaceutical compositions include, e.g., dextrin, gelatin, povidone, maltodextrin.
  • Disintegrants include, e.g., colloidal silicon dioxide, crospovidone,
  • Glidants also can be added to improve the flowability of a non-compacted solid composition and improve the accuracy of dosing. Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and references works in the field the art. Dosage forms include solid dosage forms like tablets, powders, capsules as well as liquid syrups, suspensions. The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
  • Example 1 Clopidogrel base (0.37 g) was dissolved in ethanol (3 ml) and ethanol (0.37 ml) containing hydrogen chloride are added. The reaction mixture was stirred at room temperature for 2 hours and the solvent was evaporated to dryness under reduced pressure. Then, diethyl ether (12 ml) was added and stirred at room temperature for 2 hours. The solid was collected by filtration, washed with diethyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.3 g of amorphous form of clopidogrel hydrochloride.
  • Example 2 [0035] Clopidogrel base (0.98 g) was dissolved in tetrahydrofuran (8 ml) and cone, hydrochloric acid (0.37 ml) was added. The reaction mixture was stirred at room temperature for 2 hours and the solvent was evaporated to dryness under reduced pressure. Then, diethyl ether (12 ml) was added and stirred at room temperature for 2 hours. The solid was collected by filtration, washed with diethyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.9 g of amorphous form of clopidogrel hydrochloride.
  • Example 3 Clopidogrel base (0.37 g) was dissolved in acetone (3 ml) and ethanol (0.37 ml) containing hydrogen chloride was added. The reaction mixture was stirred at room temperature for 2 hours and poured with stirring onto toluene (25 ml) at a temperature of 105 °C. The mixture was cooled, the volume was reduced to 20 ml and the mixture was stirred at room temperature 2 hours. The solid was collected by filtration, washed with diethyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.3 g of amorphous form of clopidogrel hydrochloride.
  • Example 4 [0037] Clopidogrel base (0.32 g) was dissolved in ethyl acetate (3 ml) and ethyl acetate (0.3 ml) containing hydrogen chloride was added. The reaction mixture was stirred at room temperature for 2 hours and the solvent was evaporated to dryness under reduced pressure. Then, tetrahydrofuran (3 ml) and water (0.3 ml) were added and the mixture was stirred under reflux for 24 hours. The mixture was cooled to a temperature of 0 - 5 °C with stirring. The solid was collected by filtration, dried at 35 °C in a vacuum oven for 12 hours to obtain 0.3 g of amorphous form of clopidogrel hydrochloride.
  • Example 5 Clopidogrel hydrochloride m.p .- 134 °C (0.3g) was dissolved in acetone (3 ml) at a temperature of 55 °C. ⁇ ie reaction mixture was poured with stirring onto toluene (17 ml) at a temperature of 105 °C. ⁇ ie mixture was cooled to a temperature of 25-30 °C and filtered. The filtrate was evaporated to dryness. The solid was collected, washed with diethyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.2 g of amorphous form of clopidogrel hydrochloride.
  • Example 6 Clopidogrel hydrochloride m.p .- 134 °C (0.3g) was dissolved in acetone (3 ml) at a temperature of 55-56 °C. The reaction mixture was stirred at reflux temperature for 6 hours. The solvent was evaporated to dryness under reduced pressure at a temperature of 55-56 °C. The solid was collected, washed with diethyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.2 g of amorphous form of clopidogrel hydrochloride.
  • Example 8 [0041] Clopidogrel base (0.84g) was dissolved in tert. butyl methyl ether (20ml) and hydrogen chloride gas (0.14gl) was added at -5 °C. The reaction mixture was stirred at -5 °C. After 2 hours, the solvent was evaporated to dryness under reduced pressure. Then, tert. butyl methyl ether (12 ml) was added and stirred at room temperature 2 hours. The solid which had formed was collected by filtration, washed with tert. butyl methyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 0.9g of amorphous clopidogrel hydrochloride.
  • Example 9 [0042] In 0.5-liter 3-necked flat bottom flask equipped with a thermometer, magnetic stirrer and two inlet tubes, clopidogrel base (10.6g) was dissolved in tert. butyl methyl ether (200 ml). A vigorous stream of hydrogen chloride gas (1.5g) was introduced to the reaction mixture with rapid stirring. The reaction mixture was stirred at a temperature of 0 °C for 0.4 hours. The solid which has formed was collected by filtration, washed with tert. butyl methyl ether and dried at 35 °C in a vacuum oven for 12 hours to obtain 9.3g of the amorphous form of clopidogrel hydrochloride. M.p. 92-95 °C, Cl- (argentometry) 10.3%.
  • Example 10 Clopidogrel base (0.32g) was dissolved in n-hexane (20ml) at a temperature of 45 °C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne un hydrochlorure de méthyl (+)-(S)-(2-chlorophényl)-6,7-dihydrothiéno[3,2-c]pyridine-5(4H)-acétate de forme amorphe, des procédés permettant de préparer cette forme amorphe, et une composition pharmaceutique contenant cette forme amorphe. Cette forme amorphe est utile en tant qu'inhibiteur de l'agrégation des plaquettes sanguines, et en tant qu'agent antithrombotique.
EP05756511A 2004-06-01 2005-06-01 Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique Withdrawn EP1750701A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0412172A GB0412172D0 (en) 2004-06-01 2004-06-01 Amorphous form of clopidogrel hydrochloride and its use as an antithrombotic compound
GB0418395A GB0418395D0 (en) 2004-08-18 2004-08-18 Amorphous form of clopidogrel hydrochloride and its use as an antithrombotic compound
PCT/US2005/019326 WO2005117866A1 (fr) 2004-06-01 2005-06-01 Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique

Publications (1)

Publication Number Publication Date
EP1750701A1 true EP1750701A1 (fr) 2007-02-14

Family

ID=34971760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05756511A Withdrawn EP1750701A1 (fr) 2004-06-01 2005-06-01 Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique

Country Status (3)

Country Link
EP (1) EP1750701A1 (fr)
IL (1) IL179717A0 (fr)
WO (1) WO2005117866A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074066A1 (fr) * 2004-12-30 2006-07-13 Nektar Therapeutics Formulation non cristalline comprenant du clopidogrel
WO2007029096A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Nouvelles formes polymorphes de chlorhydrate de clopidogrel
WO2007128476A1 (fr) * 2006-05-04 2007-11-15 Sandoz Ag Compositions pharmaceutiques contenant du chlorhydrate de clopidogrel
EP1970054A3 (fr) 2007-03-14 2009-06-03 Ranbaxy Laboratories Limited Comprimés de clopidogrel
EP2107061A1 (fr) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
WO2002018357A1 (fr) * 2000-08-29 2002-03-07 Rpg Life Sciences Limited Procede en recipient unique pour preparer des sels d'addition acides pharmaceutiquement acceptables de derives de 4, 5, 6, 7 - tetrahydrothieno (3,2-c) pyridine ayant une activite antithrombotique
CA2470479A1 (fr) * 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphes d'hydrogenosulfate de clopidogrel
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005117866A1 *

Also Published As

Publication number Publication date
WO2005117866A1 (fr) 2005-12-15
IL179717A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
KR100839136B1 (ko) 클로피도그렐 황산수소염의 다형
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
ES2818902T3 (es) Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina
CA2722248A1 (fr) Sel d'hydrogenosulfate de 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine et sa fabrication
US20130267574A1 (en) Polymorphic Forms of Asenapine Maleate and Processes for their Preparation
KR20040079987A (ko) 클로피도그렐 히드로클로라이드의 다형체 및 이의 항혈전화합물로서의 용도
CA2457835A1 (fr) Formes cristallines de chlorhydrate de valacyclovir
US7074928B2 (en) Polymorphs of clopidogrel hydrogensulfate
KR20070052780A (ko) 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
WO2005117866A1 (fr) Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique
CA2843773C (fr) Solvates cristallins de chlorhydrate de 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one
CA2661006A1 (fr) Formes cristallines et amorphes de tiagabine
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
EP1674468A1 (fr) Polymorphes de l'hydrobromide de clopidogrel
WO2008021518A2 (fr) Formes cristallines d'hydrochlorure de tiagabine
JP2025527820A (ja) キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
EP2121704A2 (fr) Formes polymorphes d'hydrobromure de clopidogrel
HK1192546B (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100316